UK Markets open in 3 hrs 30 mins


LSE - LSE Delayed price. Currency in EUR
Add to watchlist
5.98-0.76 (-11.28%)
At close: 08:37AM GMT


Deutscher Platz 5a
Leipzig 04103
49 341 48792 40

Full-time employees775

Key executives

NameTitlePayExercisedYear born
Mr. Jakub Julian BaranChairman of the Management Board & CEON/AN/AN/A
Mr. Tomasz Franciszek BaranVP of the Management Board & Chief Commercial OfficerN/AN/AN/A
Mr. Dirk PlagaCFO & Member of Management BoardN/AN/A1965
Santiago LuengoManaging Director of SecuvitaN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

Corporate governance

VITA 34 AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.